DNA - Cash Flow Statement - Ginkgo Bioworks Holdings, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2001
OPERATING CASH FLOW
Net Income	(547.0)	(892.9)	(2 106.4)	(1 836.6)	(126.7)	(119.9)	(2 106.4)
Depreciation & Amortization	63.0	71.6	44.4	29.1	13.9	10.8	44.4
Deferred Income Tax	(0.9)	(0.8)	(14.6)	30.2	4.1	54.7	(14.6)
Stock Based Compensation	112.3	229.9	1 930.6	1 606.0	0.5	0.8	1 930.6
Other Operating Activities	53.0	266.9	(69.3)	(20.9)	(1.1)	(1.6)	(55.0)
Change in Working Capital	0	29.8	(37.0)	(61.5)	(26.5)	10.6	55.0
Cash From Operations	(319.6)	(295.5)	(252.2)	(253.8)	(135.8)	(44.7)	(145.9)
INVESTING CASH FLOW
Capital Expenditures	(62.5)	(40.8)	(52.3)	(56.5)	(57.8)	(22.2)	0
Other Items	0.3	(39.9)	(15.1)	(16.7)	(9.3)	(52.4)	0
Cash From Investing Activities	(62.2)	(80.7)	(67.4)	(73.3)	(67.1)	(74.6)	0
FINANCING CASH FLOW
Common Stock Repurchased	0	23 K	0	(25.0)	0	(0.4)	0
Total Debt Repaid	(0.9)	(1.3)	(1.2)	(1.1)	(0.7)	198.6	0
Dividends Paid	0	0	0	0	0	0	0
Other Financing Activities	(0.8)	(1.9)	(4.0)	1 560.3	91.1	212.2	0
Cash From Financing Activities	(1.7)	(3.2)	95.3	1 534.1	90.3	410.4	0
CHANGE IN CASH
Net Change In Cash	(383.8)	(380.0)	(223.3)	1 207.1	(112.6)	291.1	(145.9)
FREE CASH FLOW
Free Cash Flow	(382.1)	(336.3)	(304.5)	(310.3)	(193.7)	(66.9)	(145.9)

Free